Alpha Tau Treats First Glioblastoma Patient Outside U.S. with Alpha DaRT — Alpha Tau Medical Ltd.

Event summary

Alpha Tau treated its first glioblastoma patient outside the U.S., at Hadassah University Medical Center in Israel.
The procedure used Alpha DaRT’s brain-specific proprietary delivery system under real-time stereotactic neuro-navigation.
Glioblastoma is the most common and aggressive primary brain cancer, with 160,000 new cases diagnosed globally each year.
The patient was treated under the ALL clinical protocol, open to patients with solid tumors in any location amenable to Alpha DaRT source delivery.

The big picture

Alpha Tau's successful treatment of a glioblastoma patient outside the U.S. marks a significant step in validating its Alpha DaRT technology for brain tumors. This procedure underscores the potential of Alpha DaRT to address one of oncology's most challenging and underserved diseases, particularly for patients with recurrent glioblastoma who have limited therapeutic options. The treatment also highlights the strategic importance of international clinical collaborations, which could accelerate regulatory approvals and commercialization efforts.

What we're watching

Clinical Validation: How the success of this procedure will impact the momentum of Alpha Tau's multicenter U.S. Recurrent GBM REGAIN trial.
Regulatory Progress: Whether the FDA clearance to proceed to full enrollment in the U.S. trial will accelerate Alpha DaRT's path to market approval.
Geographic Expansion: The pace at which Alpha Tau can expand its clinical applications beyond the U.S. and Israel, particularly in other high-need regions.